Volume 1.46 | Nov 30

Hematopoiesis News 1.46, November 30, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Specific Erythroid-Lineage Defect in Mice Conditionally Deficient for Mediator Subunit Med1  ShareThis
Here, researchers show dynamic recruitment of GATA-1, TFIIB, Mediator, and RNA polymerase II to the beta-globin locus in induced mouse erythroid leukemia cells and in an erythropoietin-inducible hematopoietic progenitor cell line. [Proc Natl Acad Sci USA]



Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]

Follow us on Twitter! @Hema_News


A Decade of Refinements in Marrow and Stem Cell Transplantation Improves Long-Term Survival of Blood Cancers
A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center. [Press release from the Fred Hutchinson Cancer Research Center discussing online prepublication in the New England Journal of Medicine]

Study Shows that Blood Stem Cells are Influenced by Their Offspring
A new study has shown that mature blood cells can communicate with, and influence the behaviour of, their stem cell ‘parents’. [Press release from The Walter and Eliza Hall Institute of Medical Research discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Adipose Tissue Produces Cells Involved in Immune Response
Researchers isolated a population of hematopoietic stem cells in adipose tissue capable of differentiating into mast cells. [Press release from PhysOrg discussing online prepublication in Stem Cells]



Alternative Promoter Usage at the Notch1 Locus Supports Ligand-Independent Signaling in T Cell Development and Leukemogenesis
Loss of the transcription factor Ikaros is correlated with Notch receptor activation in T cell acute lymphoblastic leukemia. However, the mechanism remains unknown. Researchers identified promoters in Notch1 that drove the expression of Notch1 proteins in the absence of a ligand. [Immunity]

Regulation of Hematopoietic Stem Cells by Their Mature Progeny
Here, researchers demonstrate that the megakaryocytosis and increased platelet mass in mice with mutations in the Myb or p300 genes causes reduced circulating thrombopoietin (TPO) concentration and TPO starvation of the stem-cell compartment, which is exacerbated because these cells additionally exhibit impaired responsiveness to TPO. [Proc Natl Acad Sci USA]

Synergistic Induction of PI-PLC(Beta)1 Signaling by Azacitidine and Valproic Acid in High-Risk Myelodysplastic Syndromes
In this study, researchers assessed the efficacy of the combination of azacitidine and valproic acid on inducing phosphoinositide-phospholipase C (beta)1 [PI-PLC(beta)1] expression in high-risk myelodysplastic syndrome patients. [Leukemia]

Revealing the Role of TEL/AML1 for Leukemic Cell Survival by RNAi-Mediated Silencing
Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, researchers applied RNA interference to silence TEL/AML1 in leukemic cells. [Leukemia]

Adipose Tissue as a Dedicated Reservoir of Functional Mast Cell Progenitors
In this study, researchers asked whether mast cells present in mice adipose tissue could derive from hematopoietic stem/progenitor cells identified in the tissue. [Stem Cells]

Dasatinib Plus Nutlin-3 Shows Synergistic Anti-Leukemic Activity in Both p53wild-Type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
The purpose of this study was to analyze the effect of the combination of Dasatinib, a multi-kinase inhibitor, plus Nutlin-3, a non-genotoxic activator of the p53 pathway, in primary B chronic lymphocytic leukemia patient samples and B leukemic cell line models. [Clin Cancer Res]


Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
Researchers found a substantial reduction in the hazard of death related to allogeneic hematopoietic-cell transplantation, as well as increased long-term survival, over the past decade. [N Engl J Med]

A Markov Decision Analysis of Allogeneic Hematopoietic Cell Transplantation Versus Chemotherapy in Patients with Acute Myeloid Leukemia in First Remission
The results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allogeneic hematopoietic cell transplantation in first complete remission. [Blood]

Autologous Hematopoietic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: Results of European Intergroup Randomized Trial Comparing Autografting Versus Observation
Researchers present results of a phase III randomized trial of autografting in chronic lymphocytic leukemia versus observation for responding patients after first or second line treatment. [Blood]


CGI Raises More Than $100,000 for The Leukemia and Lymphoma Society
CGI Group Inc, a leading provider of information technology and business process services raised $109,000 for the National Capital Area Chapter of The Leukemia and Lymphoma Society® (LLS) through its participation in the Team In Training® (TNT) program. [CGI Group Inc Press Release]

Helix Therapeutics Handed $2.5 Million in New Funding
Helix Therapeutics LLC, a New Haven, Conn.-based biopharmaceutical company, has landed $2.5 million in new funding from venture firm Canaan Partners and the quasi-public state funding entity Connecticut Innovations. [Mass High Tech]

Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology
Pfizer said that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase III study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). [Pfizer Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS (Listed by Date)

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada

Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States

Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States

Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States

Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

NEW  Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

NEW  PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France

NEW  World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us